Thursday, November 7, 2013

The anti-nuclear antibody

Motivation: Midway last year, the anti-nuclear antibody (ANA) test started appearing rather useless to me.  The ANA was positive at some titer in just about everyone we tested, and even when it was positive, we discarded it under the mantra of "non-specific."  What is the range of ANA in the "healthy" population?

Paper: Tan, E.M., Feltkamp, T.E.W., Smolen, J.S. et. al. "Range of antinuclear antibodies in "healthy" individuals." Arthritis & Rheumatism (1997); 40: 1601-1611.

Methods:   Fifteen international laboratories experienced in performing the ANA assay were asked to give samples from healthy individuals of different age groups and from patients with systemic lupus erythematosus (SLE), scleroderma, Sjogren's syndrome, rheumatoid arthritis (RA), and soft tissue rheumatism.  Healthy was defined as working individuals between 20-60 years of age without physical or mental disabilities.  Soft tissue rheumatism consisted of patients with non-articular pain.

Results:
Measurement Variability: Among the fifteen laboratories, inter-laboratory coefficient of variation for ANA was: 50.7% for 1:40 dilution, 44.3% for 1:80, 37.9% for 1:160, and 36% for 1:320.  Intra-laboratory variation was about three times lower than the inter-laboratory coefficient of variation.

Normal Individuals: Overall, 46.7% tested negative on ANA.  31.7% tested positive at 1:40 dilution, 13.3% at 1:80 , 5% at 1:160, and 3.3% at 1:320 dilution.

1:160 dilution: At the the 1:160 dilution, the ANA was 95% sensitive for SLE, 86.5% sensitive for scleroderma, 74% sensitive for Sjogren's, 13.5% sensitive for RA, and 7.7% sensitive for soft tissue rheumatism.  Compared to healthy controls, cutoff of 1:160 is 95% specific.

1:320 dilution: At the the 1:320 dilution, the ANA was 86.8% sensitive for SLE, 83.8% sensitive for scleroderma, 71.1% sensitive for Sjogren's, 2.7% sensitive for RA, and 3.8% sensitive for soft tissue rheumatism.  Compared to healthy controls, cutoff of 1:320 is 96.7% specific.

Discussion: A cutoff of 1:160 appears to me a more reasonable value to use to separate possible pathology from variation in healthy individuals with only 5% of healthy population having titers of ANA higher than 1:160.  To me, other surprising findings were how variable ANA is between laboratories and how poorly the ANA performs in detecting rheumatoid arthritis (only 13.5% sensitive for RA) even though it is a immunologic disorder with positive serologic markers.  These figures must, of course, be interpreted with caution because the healthy population was derived from random samples submitted to laboratories.  Aside from individuals having no physical disability, we do not know more specifics which could affect the performance of ANA.  For instance, would a population of young women or older individuals with cancer have different characteristics in the ANA?

Sunday, October 20, 2013

Fever and Pulmonary Embolism

Motivation: Clinical lore has it that pulmonary embolism (PE) causes low grade fevers and should not cause a fever as high as 103F.  While deciding on the often pondered question of whether or not a person has PE, I have seen the degree of fever sway the decision one way or the other.  But, is this true?

Paper: Stein, PD, Afzal, A, Henry, J, et. al. "Fever in Acute Pulmonary Embolism" Chest (2000); 117:39-42.

Methods: In the PIOPED (Prospective Investigation of Pulmonary Embolism Diagnosis) study, retrospective analysis was made of presence of fever in patients with angiographically proven pulmonary embolism (PE).

Results:
Cohort: There were 363 patients from PIOPED study analyzed for this study.  Fever was present in 95 patients (26%; 95% CI: 22-31%).  Of the 95 patients with fever, 43 (45.3%) did not have other causes of fever - solely attributed to PE.  There were 46 (48.4%) patients who had an alternative possible etiology of fever - 15 with malignancy, 10 with infection, 6 with recent operation (top three causes).   Six did not have further investigation (so indeterminate cause).  Fever was not more frequent in patients with pulmonary hemorrhage or infarction than in those without.

Maximum Temperature: Of the 43 patients with available information on temperature, the maximum temperature was 100 to 100.9F in 24, 101 to 101.9F in 14, 102-102.9 in 3.  One patient each had maximum temperature between 103-103.9 and greater than 104F.

Discussion: The clinical lore turns out to be mostly true - majority of patients with PE associated fever have maximum temperature less than 102F.  What I thought was most cautionary, however, is that fever is an infrequent finding in PE (present in only about a fourth).  Even among those with fever, they were just as likely to have an alternate explanation as pulmonary embolism.  What I took away from this paper is that if patients with PE have fever, they still need a thoughtful workup.

Wednesday, October 9, 2013

Taking a Chance on Chantix

Motivation: Last month, I met a man in clinic who said that his life had changed after his stroke.  Now, after years of fruitless contemplation, he was going to quit smoking.  He asked me about Chantix (generic varenicline).  Is it safe?

My instinct was to say yes.  But, the partial nicotinic agonist effects also make varenicline a sympathomimetic agent.  In patients with cardiovascular disease, are there excess side effects?  Turns out that the issue has been tested in a randomized fashion in 2010.

Paper: Rigotti, N.A., Pipe, A.L., Benowitz, N.L., et. al. "Efficacy and Safety of Varenicline for Smoking Cessation in Patients with Cardiovascular Disease." Circulation (2010); 121: 221-229.

Methods: Multi-center randomized placebo-controlled blinded trial testing varenicline (1 mg daily; quit day eight days after start of therapy) versus placebo in adult (35 to 75 years) smokers with cardiovascular disease (coronary artery disease, peripheral vascular disease, or cerebrovascular disease) existing for more than two months.  Patients with depression, severe neurological deficits from stroke, or severe renal and hepatic diseases were excluded.  Treatment group received 12 weeks of therapy.  Primary outcome was carbon monoxide confirmed abstinence between weeks 9 to 12 after start of therapy.  Patients were followed for 52 weeks.

Results:
Subjects: In total, 714 subjects were randomized to varenicline (355) or to placebo (359).  Study completion rate was 82.8% in varenicline group and 85.1% in placebo group.  Baseline characteristics were comparable between groups.  In the varenicline group, average age was 57 with 75% male and 80% white.  Average smoking history was for forty years.  For CVD, majority had CAD.  Only 4.5% had suffered a stroke.

Efficacy: The abstinence rate at weeks 9 through 12 was 47% in the varenicline group versus 13.9% in placebo (p<0.0001).  The rate of abstinence from week 9 to end of follow-up at week 52 was 19.2% for varenicline versus 7.2% for placebo (p<0.0001).

Adverse Effect: Patients on varenicline suffered more adverse effects than placebo (81.6 vs. 64.9%, CI for difference: 10.3-23.2%) resulting in more participants who stopped drug in varenicline group (9.6%) versus placebo (4.3%).  There were no differences in mortality.  The most common side effect was nausea (29.5% in varenicline vs. 8.6%).  Sleep disorder consisting of abnormal dreams, insomnia, and nightmare was significantly more frequent in treatment group (22.1%) vs placebo (9.7%).  There was a trend towards higher frequency of cardiovascular events in varenicline group (7.1% vs 5.7%) which did not reach significance.

Discussion: In summary, varenicline does not appear to increase risk of cardiovascular events significantly within the power of the study.  It was sobering to see though that after a year, only 19% will be abstinent even after being motivated enough to enroll in a trial and take a drug for twelve weeks.  Varenicline is certainly not free of adverse effects with nausea (30%) and sleep disorder (22%).  Prior to prescribing, patients need to be warned of these potentially bothersome side effects.  Also, of note, the trial was conducted in patients with stable CVD (defined as no events within the past two months).  So, I would likely wait for two to three months before prescribing varenicline to the patient seeking to stop smoking.


Sunday, September 29, 2013

Causes of Flapping

Motivation: Look - the hands are flapping.  One of the useful tests in a confused patients is to ask them to stop traffic with outstretched hands.  If the hands start flapping in a non-rhythmic way ('asterixis'), that is interpreted as proof of generalized toxic-metabolic encephalopathy.  But, then again, there is probably a neural pathway underlying this mechanism.  We often dismiss asterixis in a blase way, but can there be focal brain lesions underlying asterixis?

Paper: Degos, J-D., Verroust, J., Bouchareine, A., et. al. "Asterixis in Focal Brain Lesions"  Arch Neurol. (1979); 36: 705-707

Methods: At Henri Mondor Hospital (Creteil, France), one of the authors documented twenty cases of asterixis with focal brain lesions.  EMG was available for nine patients.

Results:
Midbrain Lesions: Four patients ranging from 38 to 62 years presenting with unilateral asterixis after abrupt onset weakness in the affected side.

Parietal Lesions: Seven cases of asterixis with pathologic proof in four occurred from parietal lesions.  These lesions could occurred on contralateral side from the asterixis and could be from mass lesions (glioblastoma, abscess, metastatic lesion) or from stroke (hemorrhagic or ischemic).

Suspected Midbrain and Parietal Lesions: Six cases with suspected lesions.  One of these cases was a right temporal glioblastoma invading the lenticular nuclei with left sided asterixis and another had an expanding right thalamic tumor with left sided asterixis.

Unclear lesions: Three cases of unilateral asterixis with accompanying unilateral weakness or numbness of unclear etiology.

EMG Recordings: During episodes of asterixis, there were 50-100 ms periods of electrical silence in both agonist and antagonist.

Discussion: This old paper shows that true asterixis is not purely a toxic-metabolic phenomenon.  Apparently, parietal, midbrain, and thalamic lesions can result in contralateral asterixis.  While this paper certainly does not suggest a pathophysiological explanation of asterixis, some important points are that: (1) asterixis appeared contralateral to the lesion meaning that usually the side with asterixis is the one that is weak or numb, (2) both cortical and deep lesions can result in asterixis,.  I think that this account provides a cautionary note of dismissing asterixis as purely toxic phenomenon.

Sunday, September 22, 2013

Interfering with RNA

Motivation: In medical school, while watching cartoons depicting disease pathophysiology pathways, I have thought many times that if we could just somehow block that damaged protein, we will cure that disease.  In mice, of course, multiple techniques exist including creating mutant breeds, transfecting with viruses, or injecting short RNA interfering sequences.  I was thrilled to read last month that such magic has for the first time been tried successfully in human beings.  Given the momentous significance of the recent trial testing RNA interference in transthyretin amyloidosis, we will cover the technique and consequences.

Paper: Coelho, T., Adams, D., Silva, A., et. al. "Safety and Efficacy of RNAi Therapy for Transthyretin Amyloidosis" NEJM (2013); 369: 819-29.

Methods: This Phase I study consisted of two parts.  In the first portion, eligible patients were older than 18 years with biopsy proven transthyretin amyloidosis with mild-to-moderate neuropathy.  Patients were excluded if they had liver, renal, or thyroid dysfunction.  These patients were injected in a blinded way with lipid nanoparticles containing RNA interfering (RNAi) sequences or with placebo.  In the second part, seventeen healthy patients were injected with a second generation lipid nanoparticle containing RNAi sequences testing for safety.

The lipid nanoparticles consisted of ionizable lipid components with RNA sequence that targets a conserved sequence at the 3' untranslated region of mRNA of Transthyretin protein (TTR).

Results:
Cohort: In the cohort with disease, there were 32 patients with 56% male and median age of 37.  Majority of participants were recruited from Portugal (23/32 patients).  The healthy volunteer cohort were all 17 male subjects with mean age of 27 (all were from England).

Amyloidosis Cohort: Patients with TTR amyloidosis treated with placebo did not have change in serum transthyretin levels.  In the group receiving 1mg/kg lipid nanoparticle dose, there was a mean reduction of 38% in serum transthyretin levels with recovery to close to baseline levels by day 28.

Healthy Volunteers: Using the second generation lipid nanoparticles, peak reduction of serum transthyretin level was reached at approximately day 10.  At 0.3 mg/kg and 0.5 mg/kg doses, the mean levels of suppression were 82.3% and 86.8%.  The serum transthyretin levels remained suppressed even at day 28.

Safety: There were no drug related serious adverse events or study drug discontinuation.  No significant changes in hematologic, liver, or renal measurements were seen.  Mild to moderate infusion reactions occurred in 7 to 20% of reactions responding to temporary interruption of infusion or administration of glucocorticosteroids.  Antibodies to pegylated lipid components were not seen.

Discussion: This trial demonstrated successful use of lipid nanoparticle RNAi to suppress transthyretin levels.   In the four week follow-up, there were remarkably no drug related side effects.  This Phase I trial, while promising, does not show efficacy of treatment on important clinical variables.  Transthyretin is primarily synthesized by the liver but is also synthesized to a smaller extent in the retina and choroid plexus.  The hepatic suppression may still leave the patient vulnerable to retinal and CNS side-effects.  In normal physiology, transthyretin is associated with retinol binding protein levels and Vitamin A levels.  Long term suppression of transthyretin may also interfere with Vitamin A metabolism.  Also, it is unclear whether repeated administration of lipid nanoparticles will generate an immunologic response.  Nonetheless, the trial is an encouraging start on selective suppression of hepatic protein synthesis.

Monday, August 26, 2013

Propofol and sepsis

Motivation: Sepsis is one of the most common issues in the ICU, and for any number of reasons, patients with sepsis also could require intubation and sedation. Practically speaking, propofol and midazolam are both commonly used in the ICU for septic patients who require sedation, weighing their risks and benefits in the individual patient. There are some benefits of propofol over midazolam in critical care patients in general (1), so I wondered whether there were risks associated with using propofol in the setting of sepsis. This discussion excludes the issue of contaminated propofol preparations. I found one paper that raised clinical concerns about the association between propofol and infection/sepsis.

Study:  Haddad S, Tamim H, Memish ZA, Arabi Y. Association of preservative-free propofol use and outcome in critically ill patients. Am J Infect Control. 2011 Mar;39(2):141-7. 

Design: Nested cohort study of patients who were enrolled in a randomized control trial on another topic (comparing different regimens of insulin therapy). Patients who were on propofol were compared to those who were not on propofol, in terms of baseline characteristics and outcomes. ICU-acquired infections were defined as those found at least 48 hours after ICU admission and up to 48 hours after discharge, while ICU-acquired sepsis was defined as per standard criteria (2).

Results: There were differences in baseline characteristics between the two groups of patients; compared to no propofol, propofol group were more likely to be mechanically ventilated but less likely to have severe illness, chronic renal disease, immunosuppression or cardiovascular disease. In adjusted statistical analysis, propofol use was associated with increased risk of ICU-acquired infection (95 CI 1.17-3.05, p=0.009), and ICU-acquired severe sepsis and septic shock (95 CI 1.12-3.28,p=0.02). There were no statistically significant differences in ICU or hospital length of stay or ICU or hospital mortality (2). 

Discussion: This study had convincing evidence as above for a relationship between propofol use and infections, and discusses potential reasons why propofol may be associated with increased risk of infectious including impairment of host immune cell function, increased lipid levels affecting mitochondrial oxygen use, growth of bacteria in propofol emulsion, increased lipid caloric intake (2); however, it is important to emphasize that these are potential reasons based on studies or observations in other contexts that are not necessarily generalizable to the septic ICU patient. In terms of study limitations, it is important to note that the study showed a statistical association (not causation) between use of propofol and increased risk of ICU-acquired infection or sepsis in a post-hoc study on a trial designed for another indication (2). Noted that this study did not compare propofol versus midazolam, nor did I find a similarly designed study for midazolam.

I was surprised to see that there were several animal studies that showed benefit of propofol (versus no propofol) in animal models of sepsis. A few examples of these studies are here; most of the sample sizes are modest. In an animal study specifically designed to study the effect of propofol on a rat model of sepsis (cecal ligation and puncture), rats treated with early or late propofol had statistically significant higher survival rates than rats without propofol treatment (3). Propofol-treated rats also had statistically significant lower levels of ALT, AST, BUN, Cr and CK (3). In the same rat model of sepsis, rats treated with propofol had improved hypotension, lower plasma levels of TNF-alpha, IL-6, and more suppression of NF-kappaB activation (4). Another study reported that midazolam had an overall anti-inflammatory effect in a macrophage cell line through various mechanisms (5).

Looking for more studies of animal models of sepsis and sedation, I found a paper on the same rat model of sepsis comparing the effects of propofol and midazolam on neutrophil function (6). In both early and late time points of sepsis, propofol and midazolam decreased hydrogen peroxide production by neutrophils with propofol associated with statistically signficantly more decreased production than midazolam (6). These results suggest at least in the in vitro context that propofol might attenuate neutrophil function in this rat model of sepsis, favoring midazolam over propofol if results could be extrapolated to clinical context (6). Also, it was very interesting to note in this study that there was negligible effect of the lipid propofol carrier on neutrophil hydrogen peroxide production (6).

Conclusion: Overall, there lacks definitive evidence comparing propofol and midazolam in ICU patients with sepsis; however, one clinical study brought up concerning associations between propofol and ICU-related infection (2), while one animal model study showed that midazolam would be better than propofol in rat models of sepsis as it interfered less with neutrophil function (6). These concerns should be taken into account when weighing the risks and benefits of midazolam versus propofol for the septic ICU patient.

References:
1.     Carrasco G, Molina R, Costa J, Soler JM, CabrĂ© L. Propofol vs midazolam in short-, medium-, and long-term sedation of critically ill patients. A cost-benefit analysis. Chest. 1993 Feb;103(2):557-64.
2.     Haddad S, Tamim H, Memish ZA, Arabi Y. Association of preservative-free propofol use and outcome in critically ill patients. Am J Infect Control. 2011 Mar;39(2):141-7.
3.     Bao HG, Li S. Effects of propofol on the outcomes of rats with sepsis. J Surg Res. 2011 Jun 1;168(1):e111-5. doi: 10.1016/j.jss.2010.12.034. Epub 2011 Jan 22.
4.     Song XM, Wang YL, Li JG, Wang CY, Zhou Q, Zhang ZZ, Liang H. Effects of propofol on pro-inflammatory cytokines and nuclear factor kappaB during polymicrobial sepsis in rats. Mol Biol Rep. 2009 Nov;36(8):2345-51. doi: 10.1007/s11033-009-9456-z. Epub 2009 Feb 4.
5.     Kim SN, Son SC, Lee SM, Kim CS, Yoo DG, Lee SK, Hur GM, Park JB, Jeon BH. Midazolam inhibits proinflammatory mediators in the lipopolysaccharide-activated macrophage. Anesthesiology. 2006 Jul;105(1):105-10.
6.     Inada T, Taniuchi S, Shingu K, Kobayashi Y, Fujisawa J, Nakao S. Propofol depressed neutrophil hydrogen peroxide production more than midazolam, whereas adhesion molecule expression was minimally affected by both anesthetics in rats with abdominal sepsis. Anesth Analg. 2001 Feb;92(2):437-41.

Friday, August 16, 2013

Abdominal pain and seizures

Motivation: A man walks in to the hospital with seizures also complains of periodic stomach pain.  I wonder could it also be a seizure?  After all, migraines in children are clearly linked to episodes of abdominal pain.  Could epileptic discharges create a similar phenomenon?

Turns out that this issue has been thought of by many - in fact, Trousseau had also thought about the issue in 1868.  Reviewed here is a compilation of the common clinical presentation.

Paper: Zinkin, NT, Peppercorn, MA. "Abdominal epilepsy" Best Practice & Research Clinical Gastroenterology (2005); 19(2): 263-274.

Methods: Review of 36 reported cases in english literature.  Patients were required to have paroxysmal EEG abnormalities with correlated clinical spells.

Results:
Clinical Characteristics: In meta-analysis of 36 published cases, most frequent feature was a sharp pain (86%) commonly in peri-umbilical and upper abdominal pain.  Nausea and vomiting was an infrequent feature in 28% followed by diarrhea (5%) and bloating (3%).  Besides abdominal pain, some disturbance in consciousness was observed in 64% ranging from generalized seizures to dizziness.  Duration of seizures was at most a few minutes.  EEG did not have a consistent localization for inter-ictal epileptiform activity.

Discussion: I think that abdominal epilepsy is worth considering as a diagnosis in someone with bouts of brief abdominal pain with some change in consciousness/"funny" feeling.  There are many people - often hard to treat people - with unexplained abdominal pain.  Some get unsatisfactory diagnosis of irritable bowel syndrome or somatoform disorders.  If there is no other explanation, an EEG may be in order.